We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.21%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$290M
AUM Growth
+$16.2M
Cap. Flow
-$4.34M
Cap. Flow %
-1.5%
Top 10 Hldgs %
25.51%
Holding
174
New
37
Increased
46
Reduced
48
Closed
32

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$3.3M
2
GEV icon
GE Vernova
GEV
+$2.82M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$2.76M
4
DYN icon
Dyne Therapeutics
DYN
+$2.61M
5
AMZN icon
Amazon
AMZN
+$2.59M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$6M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$4.02M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$3.97M
4
MRUS
Merus
MRUS
+$2.23M
5
META icon
Meta Platforms (Facebook)
META
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 46.45%
2 Technology 15.69%
3 Consumer Discretionary 9.1%
4 Industrials 4.98%
5 Financials 4.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
101
DELISTED
Apellis Pharmaceuticals
APLS
$1.04M 0.36%
35,975
+28,409
+375% +$1.05M
CRH icon
102
CRH
CRH
$67.4B
$1.03M 0.36%
11,100
+1,000
+10% +$84K
PGR icon
103
Progressive
PGR
$123B
$1.02M 0.35%
+4,000
New +$930K
VERA icon
104
Vera Therapeutics
VERA
$2.17B
$973K 0.34%
22,010
+12,848
+140% +$488K
ADBE icon
105
Adobe
ADBE
$105B
$932K 0.32%
1,800
-1,300
-42% -$713K
FCNCA icon
106
First Citizens BancShares
FCNCA
$25.4B
$920K 0.32%
+500
New +$954K
CNTA
107
DELISTED
Centessa Pharmaceuticals
CNTA
$737K 0.25%
+46,116
New +$565K
VRNA
108
DELISTED
Verona Pharma
VRNA
$683K 0.24%
23,739
-8,710
-27% -$214K
ALV icon
109
Autoliv
ALV
$8.96B
$672K 0.23%
+7,200
New +$717K
PRAX icon
110
Praxis Precision Medicines
PRAX
$10.3B
$630K 0.22%
+10,951
New +$592K
BEKE icon
111
KE Holdings
BEKE
$18.7B
$607K 0.21%
30,507
+6,800
+29% +$100K
KYMR icon
112
Kymera Therapeutics
KYMR
$9.11B
$603K 0.21%
+12,743
New +$563K
CGON icon
113
CG Oncology
CGON
$6.83B
$594K 0.2%
+15,734
New +$552K
GERN icon
114
Geron
GERN
$1.05B
$578K 0.2%
127,284
-52,515
-29% -$239K
RNAM
115
DELISTED
Avidity Biosciences
RNAM
$574K 0.2%
+12,504
New +$543K
JD icon
116
JD.com
JD
$43.1B
$571K 0.2%
14,283
-4,900
-26% -$135K
TCOM icon
117
Trip.com Group
TCOM
$29.1B
$568K 0.2%
9,556
-2,200
-19% -$102K
BIDU icon
118
Baidu
BIDU
$35.9B
$567K 0.2%
5,386
+1,200
+29% +$106K
OCUL icon
119
Ocular Therapeutix
OCUL
$2.14B
$566K 0.2%
65,027
+3,168
+5% +$26.1K
ABVX
120
Abivax
ABVX
$11.1B
$565K 0.19%
49,064
-445
-0.9% -$5.33K
LI icon
121
Li Auto
LI
$12.4B
$562K 0.19%
+21,900
New +$445K
SLNO
122
DELISTED
Soleno Therapeutics
SLNO
$560K 0.19%
+11,085
New +$531K
ITCI
123
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$548K 0.19%
7,496
-16,841
-69% -$1.27M
DNTH icon
124
Dianthus Therapeutics
DNTH
$6.07B
$542K 0.19%
+19,808
New +$552K
CGEM icon
125
Cullinan Oncology
CGEM
$1.26B
$534K 0.18%
+31,893
New +$566K
3 4
5
6 7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q3 2024 Portfolio in Review

As of Q3 2024, HighVista Strategies held 174 positions worth $290M, up 5.9% from $274M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

HighVista Strategies's Q3 2024 filing shows 37 new, 46 increased, 48 reduced and 32 closed positions. Its largest new stake was Amgen: 10,101 shares worth $3.25M. The largest sale was Insmed, an estimated $6M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 44% a quarter earlier, followed by Technology and Consumer Discretionary.

  • HighVista Strategies's largest Q3 2024 buy was Amgen: 10,101 shares worth $3.25M.
  • HighVista Strategies added most to Protagonist Therapeutics in Q3 2024, an estimated $2.76M increase.
  • HighVista Strategies's biggest Q3 2024 reduction was Insmed, cutting an estimated $6M.
  • HighVista Strategies fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $4.02M.
  • HighVista Strategies's ten largest holdings make up 26% of its $290M portfolio in Q3 2024.
  • HighVista Strategies opened 37 new positions and closed 32 in Q3 2024.
  • HighVista Strategies's portfolio value rose 5.9% quarter-over-quarter to $290M.

Based on HighVista Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.